Multiples Myelom - Neuigkeiten der DGHO Jahrestagung 2024

00:00 Welcome by Klaus Eisenbeisz (Myelom.Online e.V.), Prof. Dr. med. Monika Engelhardt (University Hospital Freiburg) and moderator Dr. med. Jens Ulrich Rüffer 01:51 Young Investigator Award: Efficacy of CAR T-cell therapies in patients with multiple myeloma and prior exposure to bispecific antibodies – results of a multicenter retrospective study in Germany 06:14 Multiple myeloma – developments in diagnostics and therapy 11:06 Multiple myeloma and myelofibrosis: Targeted and symptom-oriented treatment and latest developments in vaccinations for patients in hematology 16:44 Study update: DREAMM-7: Subgroup analyses of the Phase 3 trial of belantamab mafodotin (Belamaf) + bortezomib and dexamethasone vs. daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma 19:38 Early suppression of free light chains after BCMA-CAR-T therapy in multiple myeloma as a predictive biomarker for Remission duration 23:29 What is the optimal treatment duration for BCMA bispecific antibodies in multiple myeloma? 26:27 SARS-CoV-2 immune responses in patients with multiple myeloma undergoing lenalidomide maintenance therapy compared to healthy controls. 33:48 Closing remarks - Send us your feedback via email! [email protected]